Advaxis ($ADXS), on a partnering spree after joining with Merck ($MRK) and AstraZeneca ($AZN) to test its cancer vaccine candidates in immunotherapy combos, has teamed up with Incyte ($INCY) to trial one of its prospects in cervical cancer. Under the deal, the two will split costs of a Phase II study testing Advaxis' ADXS-HPV and Incyte's epacadostat (formerly INCB24360). The pair plans to get started later this year, using results to determine whether the tandem should move into Phase III. Release | More